[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 8 of about 8
1. Crawford JH, Eikelboom JW, McQuillan A: Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia. Eur J Haematol; 2002 Nov-Dec;69(5-6):315-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia.
  • We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe bullous eruption, following successive cycles of high-dose cytarabine for the treatment of acute lymphoblastic leukaemia.
  • Contrary to previous recommendations, our experience cautions against the further use of high-dose cytarabine in patients who develop PPE, and is a timely reminder of the potential toxicity of this agent, which is now increasingly being used as first-line treatment in the management of haematologic malignancies.
  • [MeSH-major] Cytarabine / adverse effects. Paresthesia / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Skin Diseases / chemically induced
  • [MeSH-minor] Adult. Drug Eruptions / etiology. Erythema / chemically induced. Foot Dermatoses / chemically induced. Hand Dermatoses / chemically induced. Humans. Male. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12460237.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine
  •  go-up   go-down


2. Benesch M, Sovinz P, Krammer B, Lackner H, Mann G, Schwinger W, Gadner H, Urban C: Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol; 2007 Apr;29(4):222-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied feasibility and toxicity of IT administered liposomal cytarabine on a compassionate basis in 5 patients (male, n=4; female, n=1; age at diagnosis 5 to 18 y) with recurrent acute lymphoblastic leukemia (n=3), primary refractory acute myeloid leukemia (n=1), or relapsed medulloblastoma (n=1).
  • If administered simultaneously to other neurotoxic drugs, IT liposomal cytarabine may contribute to neurologic side effects in patients who had received prior intensive CNS-directed therapy.
  • IT liposomal cytarabine should, therefore, be used cautiously, if a patient receives other potentially neurotoxic drugs simultaneously.

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414563.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down


3. Gottfredsson M, Steingrímsdóttir H: Disseminated invasive aspergillosis in a patient with acute leukaemia. Acta Biomed; 2006;77 Suppl 2:10-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated invasive aspergillosis in a patient with acute leukaemia.
  • A 46-year-old previously healthy woman was diagnosed with acute lymphoblastic leukaemia.
  • Following this infection the patient developed recurrent fever and new pulmonary infiltrates were noted.
  • Bronchoscopy was performed and treatment was administered with liposomal amphotericin B (L-AmB, AmBisome) for two days, but was complicated by acute renal failure.
  • [MeSH-major] Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Aspergillosis / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Acute Kidney Injury / chemically induced. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bacteremia / complications. Bacteremia / drug therapy. Chlamydophila Infections / complications. Chlamydophila Infections / drug therapy. Chlamydophila pneumoniae. Doxorubicin / administration & dosage. Drug Resistance, Multiple, Fungal. Drug Therapy, Combination. Echinocandins. Fatal Outcome. Female. Humans. Immunocompromised Host. Liposomes. Lung Diseases, Fungal / complications. Lung Diseases, Fungal / drug therapy. Medical Futility. Methotrexate / administration & dosage. Middle Aged. Neuroaspergillosis / drug therapy. Neuroaspergillosis / etiology. Peptides, Cyclic / administration & dosage. Peptides, Cyclic / therapeutic use. Pneumonia, Bacterial / complications. Pyrimidines / therapeutic use. Streptococcal Infections / complications. Streptococcal Infections / drug therapy. Triazoles / therapeutic use. Vincristine / administration & dosage. Voriconazole

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Acta Biomed. 2006;77 Suppl 4:following 33
  • (PMID = 16918060.001).
  • [ISSN] 0392-4203
  • [Journal-full-title] Acta bio-medica : Atenei Parmensis
  • [ISO-abbreviation] Acta Biomed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antifungal Agents; 0 / Echinocandins; 0 / Liposomes; 0 / Peptides, Cyclic; 0 / Pyrimidines; 0 / Triazoles; 0 / liposomal amphotericin B; 5J49Q6B70F / Vincristine; 7XU7A7DROE / Amphotericin B; 80168379AG / Doxorubicin; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Jameel A, Jamil SN: Safety of cytotoxic chemotherapy during pregnancy. J Pak Med Assoc; 2007 Sep;57(9):449-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six patients (33%) had breast cancer, four (22%) had chronic myeloid leukaemia, two (11%) had Hodgkin's disease, two (11%) had acute myeloid leukaemia and one each had recurrent ovarian carcinoma (5.7%), soft-tissue sarcoma (5.7%), acute lymphoblastic leukaemia (5.7%) and non-Hodgkin's lymphoma (5.7%).
  • Remaining 12/14 (86%) patients gave birth to live, healthy babies and no foetal malformations were observed.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cytotoxins / adverse effects. Drug-Related Side Effects and Adverse Reactions. Pregnancy Complications. Pregnancy Outcome
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Neoplasms / drug therapy. Pregnancy. Pregnancy Trimester, Second. Prospective Studies. Time Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18072640.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytotoxins
  •  go-up   go-down


5. Qureshi A, Mitchell C, Richards S, Vora A, Goulden N: Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe. Br J Haematol; 2010 May;149(3):410-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the incidence and outcome of venous thrombosis (VT) in the UK acute lymphoblastic leukaemia (ALL) 2003 trial.
  • There were no episodes of bleeding or recurrent thrombosis.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Asparaginase / adverse effects. Venous Thrombosis / chemically induced
  • [MeSH-minor] Adolescent. Anticoagulants / therapeutic use. Child. Child, Preschool. Feasibility Studies. Female. Heparin, Low-Molecular-Weight / therapeutic use. Humans. Infant. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prospective Studies

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201945.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300130; United Kingdom / Medical Research Council / / MC/ U137686856
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents; 0 / Heparin, Low-Molecular-Weight; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


6. Demaria RG, Dürrleman N, Rispail P, Margueritte G, Macia JC, Aymard T, Frapier JM, Albat B, Chaptal PA: Aspergillus flavus mitral valve endocarditis after lung abscess. J Heart Valve Dis; 2000 Nov;9(6):786-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 16-year-old male with bone marrow failure due to chemotherapy for recurrent acute lymphoblastic leukemia developed an abscess in the lower lobe of the left lung draining through a bronchogastric fistula, as well as mitral valve endocarditis with large vegetations.
  • [MeSH-minor] Adolescent. Heart Valve Diseases / diagnosis. Heart Valve Diseases / microbiology. Heart Valve Diseases / surgery. Humans. Male. Opportunistic Infections / diagnosis. Opportunistic Infections / drug therapy

  • Genetic Alliance. consumer health - Endocarditis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Endocarditis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11128785.001).
  • [ISSN] 0966-8519
  • [Journal-full-title] The Journal of heart valve disease
  • [ISO-abbreviation] J. Heart Valve Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Aschoff P, Häntschel M, Oksüz M, Werner MK, Lichy M, Vogel W, Pfannenberg C: Integrated FDG-PET/CT for detection, therapy monitoring and follow-up of granulocytic sarcoma. Initial results. Nuklearmedizin; 2009;48(5):185-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Granulocytic sarcomas (GS) are rare extramedullary manifestations of myeloid or lymphoblastic leukaemia.
  • RESULTS: 52 untreated or recurrent GS lesions were detected by FDG-PET/CT and all showed an increased FDG uptake with a mean SUVmax and SUVavg of 5.1 and 3.4, respectively.
  • PET/CT identified recurrent GS in 3 patients.
  • Therefore, FDG-PET/CT appears to be a promising diagnostic and monitoring tool in the management of patients with GS.
  • [MeSH-minor] Adult. Female. Fluorodeoxyglucose F18. Follow-Up Studies. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / radiography. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / radionuclide imaging. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / radiography. Leukemia, Myeloid, Acute / radionuclide imaging. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19710955.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


8. Gong H, Liu WL, Zhou JF, Xu HZ: [Expression of mitosis checkpoint gene CHFR in acute leukemia]. Zhonghua Yi Xue Za Zhi; 2005 Apr 27;85(16):1085-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of mitosis checkpoint gene CHFR in acute leukemia].
  • OBJECTIVE: To investigate the expression of mitosis checkpoint gene CHFR in adult patients with acute leukemia (AL) and its clinical significance.
  • METHODS: Four ml of bone marrow was extracted from 65 AL patients, 38 males and 27 females, with the median age of 35, 43 with acute myelocytic leukemia (AML) and 22 with acute lymphocytic leukemia (ALL), 45 de novo patients and 20 recurrent patients, and 8 normal donor of allogeneic bone marrow transplantation as controls.
  • (1) The levels of CHFR protein and mRNA were correlated with the cumulative percentages of cells in S phases. (2) The expression level of CHFR protein in 40.6% (13/32) of the AL patients and that of the CHFR mRNA in 60.0% (27/45) of the AL patients were both significantly lower than those of the normal controls. (3) The mean expression level of CHFR protein in the recurrent acute lymphoblastic leukemia (ALL) was 0.71, significantly higher than that of the de novo group (0.38, t = 2.54, P = 0.017). (4) The complete remission (CR) rates in the AL patients with high expression levels of CHFR protein and mRNA were 30.2% and 42.4% respectively, significantly lower than those in the AL patients with low expression levels (88.6% and 85.4% respectively, both P < 0.05).
  • CONCLUSION: By affecting mitotic checkpoint function, CHFR inactivation plays a key role in tumorigenesis in adult patients with acute leukemia.
  • Moreover, the aberrant expression of CHFR appears to be a good molecular marker to predict the sensitivity of acute leukemia to chemotherapy.
  • [MeSH-major] Cell Cycle Proteins / biosynthesis. Leukemia, Myeloid, Acute / genetics. Neoplasm Proteins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / pharmacology. Cell Cycle. Child. Drug Resistance. Female. HL-60 Cells. Humans. Male. Middle Aged. Mitosis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029562.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CHFR protein, human; 0 / Cell Cycle Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down






Advertisement